Comparative Pharmacology
Head-to-head clinical analysis: ALPRAZOLAM versus CLOBAZAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALPRAZOLAM versus CLOBAZAM.
ALPRAZOLAM vs CLOBAZAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Positive allosteric modulator of GABA-A receptors; enhances GABA inhibitory neurotransmission by binding to benzodiazepine site on GABA-A receptor, increasing chloride ion conductance.
Clobazam is a benzodiazepine that enhances the effect of GABA at the GABA-A receptor, increasing chloride ion conductance and neuronal hyperpolarization. It has a high affinity for the α2 subunit, which may contribute to its anticonvulsant effects.
0.25-0.5 mg orally 3 times daily; maximum 4 mg/day in divided doses.
10-60 mg orally once daily, divided into two doses. Typical starting dose: 10 mg twice daily.
MODERATE Risk
MODERATE Risk
12-15 hours (mean ~13 hours); prolonged in elderly (up to 19 hours) and hepatic impairment (up to 20-30 hours); clinical context: allows once- to twice-daily dosing, but risk of accumulation with high doses or in vulnerable populations
Clinical Note
moderateClobazam + Estrone sulfate
"The serum concentration of Estrone sulfate can be decreased when it is combined with Clobazam."
Clinical Note
moderateClobazam + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Clobazam is combined with Fluticasone propionate."
Clinical Note
moderateAlprazolam + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Alprazolam is combined with Fluticasone propionate."
Clinical Note
moderateClobazam: 36–42 hours; N-desmethylclobazam: 71–82 hours. Steady state achieved in 5–10 days.
Renal (approximately 80% as metabolites, <20% unchanged); fecal (minor, ~7%)
Renal: ~82% as metabolites (mainly N-desmethylclobazam and hydroxylated metabolites), unchanged clobazam <1%; fecal: ~11%.
Category D/X
Category C
Benzodiazepine
Benzodiazepine
Alprazolam + Haloperidol
"The risk or severity of adverse effects can be increased when Alprazolam is combined with Haloperidol."